Home » Stocks » Aligos Therapeutics

Aligos Therapeutics, Inc. (ALGS)

Stock Price: $14.76 USD -0.09 (-0.61%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $14.60 -0.16 (-1.08%) Oct 19, 7:33 PM

Stock Price Chart

Key Info

Market Cap 498.86M
Revenue (ttm) n/a
Net Income (ttm) -73.06M
Shares Out 36.89M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $14.76
Previous Close $14.85
Change ($) -0.09
Change (%) -0.61%
Day's Open 14.74
Day's Range 14.00 - 15.00
Day's Volume 342,381
52-Week Range 13.63 - 17.50

More Stats

Market Cap 498.86M
Enterprise Value 423.89M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.89M
Float 14.98M
EPS (basic) n/a
EPS (diluted) -1.98
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -73.06M
Free Cash Flow n/a
Net Cash 74.96M
Net Cash / Share 2.22
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-54.04-13.66
Net Income-52.26-13.93
Shares Outstanding18.8311.11
Earnings Per Share-2.78-1.25
Operating Cash Flow-46.77-6.05
Capital Expenditures-2.79-2.52
Free Cash Flow-49.55-8.57
Cash & Equivalents11891.36
Total Debt14.3313.86
Net Cash / Debt10477.50
Book Value-64.89-13.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aligos Therapeutics, Inc.
Country United States
Employees 67
CEO Lawrence M. Blatt

Stock Information

Ticker Symbol ALGS
Stock Exchange NASDAQ
Sector Health Technology
Industry Pharmaceuticals: Major
Unique Identifier NASDAQ: ALGS
IPO Date October 16, 2020


Aligos Therapeutics develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.